Overall, the reported additional cohorts of the NA-PHER2 study illustrate the course of Ki67 during a 16-weeks long therapy targeting cdk4/6 and HER2, and provide potentially useful information for the ongoing effort of defining novel and chemo-free treatments for women with HER2 positive breast cancer and hormone receptor positive breast cancer. This evidence concerns the gene CDK4 and breast carcinoma.